TW546145B - Agent for treating visual cell function disorder with macrolide compound as active ingredient - Google Patents

Agent for treating visual cell function disorder with macrolide compound as active ingredient Download PDF

Info

Publication number
TW546145B
TW546145B TW088122634A TW88122634A TW546145B TW 546145 B TW546145 B TW 546145B TW 088122634 A TW088122634 A TW 088122634A TW 88122634 A TW88122634 A TW 88122634A TW 546145 B TW546145 B TW 546145B
Authority
TW
Taiwan
Prior art keywords
group
active ingredient
agent
eye
macrolide compound
Prior art date
Application number
TW088122634A
Other languages
English (en)
Chinese (zh)
Inventor
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd, Fujisawa Pharmaceutical Co filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of TW546145B publication Critical patent/TW546145B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW088122634A 1998-12-24 1999-12-22 Agent for treating visual cell function disorder with macrolide compound as active ingredient TW546145B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
TW546145B true TW546145B (en) 2003-08-11

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088122634A TW546145B (en) 1998-12-24 1999-12-22 Agent for treating visual cell function disorder with macrolide compound as active ingredient

Country Status (13)

Country Link
EP (1) EP1140134A1 (fr)
JP (1) JP2002542150A (fr)
KR (1) KR20010099928A (fr)
CN (1) CN1224420C (fr)
AR (1) AR022017A1 (fr)
AU (1) AU781049B2 (fr)
BR (1) BR9917113A (fr)
CA (1) CA2356382A1 (fr)
MX (1) MXPA01006449A (fr)
NO (1) NO20013146L (fr)
NZ (1) NZ513111A (fr)
TW (1) TW546145B (fr)
WO (1) WO2000038703A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
WO2003061519A2 (fr) 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Procedes et compositions preservant la viabilite des cellules photoreceptrices de l'oeil
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
WO2007019427A2 (fr) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methodes et compositions permettant de preserver la viabilite des cellules photoreceptrices
EP2001438A2 (fr) 2006-02-09 2008-12-17 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20210338770A1 (en) * 2018-10-15 2021-11-04 Osaka University Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003049A1 (fr) * 1990-08-23 1992-03-05 New York University Procedes et compositions de traitement de maladies induites par les lymphocytes t
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
JP2002511868A (ja) * 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド 増殖性硝子体網膜症を治療するためのカルシウム遮断薬
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
AU1690600A (en) 2000-07-31
NO20013146L (no) 2001-08-20
NZ513111A (en) 2003-10-31
WO2000038703A1 (fr) 2000-07-06
JP2002542150A (ja) 2002-12-10
EP1140134A1 (fr) 2001-10-10
AU781049B2 (en) 2005-05-05
KR20010099928A (ko) 2001-11-09
NO20013146D0 (no) 2001-06-22
CN1224420C (zh) 2005-10-26
CA2356382A1 (fr) 2000-07-06
AR022017A1 (es) 2002-09-04
BR9917113A (pt) 2001-10-23
MXPA01006449A (es) 2002-04-24
CN1352565A (zh) 2002-06-05

Similar Documents

Publication Publication Date Title
US11433137B2 (en) Compounds for treating cancer
TW546145B (en) Agent for treating visual cell function disorder with macrolide compound as active ingredient
JP2536248B2 (ja) 水性外用液剤
US20070149548A1 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
US20100144858A1 (en) Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
CZ125198A3 (cs) Použití derivátu kyseliny pipekolinové a jeho farmaceuticky přijatelných solí pro výrobu léčiva pro ovlivňování neurologické aktivity u zvířete
EP1237577A2 (fr) Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection
JP2011256195A (ja) 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト
JPH10513463A (ja) うっ血性心不全の治療へのカルバゾール化合物の利用
US20030166661A1 (en) L-arginine and phosphodiesterase (PDE) inhibitor synergism
CA2756864A1 (fr) Agent prophylactique ou therapeutique des retinopathies comprenant un peptide inhibiteur de jnk (c-jun n-terminal kinase), methode de prevention ou de traitement des retinopathies, et utilisation du peptide
TWI230066B (en) A pharmaceutical composition for treating dry eye
JPH07504659A (ja) Ace阻害剤及び利尿剤の併用
US7276514B2 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
KR20010013690A (ko) 동맥 혈전증의 치료와 예방을 위한 조성물과 그 조성물단독 및/또는 혈소판 응집방지제와 결합한 인자 Xa억제제의 사용법
JP2012131829A (ja) そう痒状態の処置のためのmglur5アンタゴニストの使用
EP1956908A2 (fr) Compositions et procedes de traitement
US6177450B1 (en) Synergizing combination having an antagonist effect on NKI and NK2 receptors
WO2002085372A1 (fr) Medicaments et trousses medicales
MXPA03011847A (es) Uso de zonisamida en cefalea.
Gradin et al. Cardiovascular effects in the Sprague‐Dawley rat of 8− hydroxy− 2 (di‐N‐propylamino) tetralin, a selective 5− hydroxytryptamine receptor agonist
NL8700191A (nl) Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.
Grunberg Antiemetic Drugs: Essential Pharmacology
AU2006330599B2 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
KR20240122521A (ko) 만성 신장 질환 치료용 알도스테론 신타아제 억제제

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees